Hematologics

Executive Summary

Hematologics is a private Seattle-based diagnostics company specializing in flow cytometry-based hematology testing. The company provides diagnostic and monitoring services for myeloid disorders, leveraging standardized flow-based panels to assess phenotypic abnormalities. In January 2024, Hematologics completed an update to harmonize its diagnostic and monitoring myeloid panels, enhancing data linkage and phenotypic assessment. As a niche player in hematology diagnostics, Hematologics serves clinical laboratories and healthcare providers, but its low public profile and lack of disclosed funding or revenue limit visibility into its growth trajectory. The company's focus on assay standardization may improve clinical utility, but competitive pressures from larger diagnostics firms and evolving test methodologies pose risks. Without disclosed partnerships or pipeline expansions, Hematologics appears to be a stable but slow-growth entity in the diagnostic space.

Upcoming Catalysts (preview)

• TBDLaunch of new flow cytometry panels for lymphoid or rare hematologic disorders50% success